NYSE:OLN
NYSE:OLNChemicals

Does Olin (OLN) Still Offer Value After Recent Share Price Rebound

If you are wondering whether Olin's current share price fairly reflects the business, this article will walk through what the numbers actually say about value. Over the short term the stock has had mixed moves, with a 1.9% decline over the last 7 days, a 15.3% gain over the last 30 days, and an 8.6% return year to date. The 1 year and 3 year returns of 28.2% and 55.6% respectively have been weaker, and the 5 year return sits around flat at 0.2%. Recent price moves sit against a backdrop of...
TSX:HBM
TSX:HBMMetals and Mining

Assessing Hudbay Minerals (TSX:HBM) Valuation After Weaker 2025 Production Update

Why Hudbay’s latest production update matters Hudbay Minerals (TSX:HBM) has drawn fresh attention after releasing preliminary production figures for the fourth quarter and full year 2025, showing lower copper, gold, zinc and silver volumes compared with the prior period. See our latest analysis for Hudbay Minerals. The production update lands after a strong run in Hudbay Minerals’ share price, with a 30 day share price return of 19.62% and a 90 day gain of 36.32%. The 1 year total shareholder...
NYSE:CPAY
NYSE:CPAYDiversified Financial

Is Corpay’s High Five-Year ROE Reshaping The Investment Case For Corpay (CPAY)?

In recent commentary, Corpay highlighted its evolution from the former FLEETCOR brand into a diversified B2B payments provider spanning vehicle, corporate, and lodging spend management, underpinned by several years of steady revenue growth and strong profitability metrics. An interesting takeaway is Corpay’s average return on equity of 31.1% over the last five years, which points to an efficient business model and a reinforced competitive position in commercial payments. Next, we’ll examine...
NasdaqGS:SYRE
NasdaqGS:SYREBiotechs

How Does Spyre Therapeutics’ New CCO Shape SYRE’s Path From Pipeline To Commercial Strategy?

Spyre Therapeutics recently expanded its leadership team by appointing former Amgen executive Kate Tansey Chevlen as Chief Commercial Officer, adding nearly two decades of global biopharma commercial experience to guide its late-stage development and commercialization plans. This hire, paired with the company’s 2026 roadmap of six planned proof-of-concept readouts across its SKYLINE and SKYWAY trials, highlights a coordinated push to convert scientific programs into potential market-ready...